Streetbeat News

Earnings

HBIO

Harvard Bioscience (NASDAQ:HBIO) reported Q2 adjusted earnings of $0.04 per share, missing the analyst consensus estimate of $0.05 by 20%. The company also reported quarterly sales of $28.80 million, missing the analyst consensus estimate of $29.50 million by 2.37%. This represents a decrease in both earnings and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:20 am

CECO

CECO Environmental Corp. has increased its FY23 revenue guidance to $500M-$525M, up from the previous expectation of exceeding $485M. The company also updated its FY23 adjusted EBITDA forecast to be between $50M and $55M, a 25% increase at the mid-point year over year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:19 am

STGW

Stagwell has reduced its FY23 organic net revenue growth forecast from 7.5%-10% to 0%-2%. It has also lowered its adjusted EPS forecast from $0.90-$1.05 to $0.76-$0.85, which aligns with the consensus estimate of $0.85.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:19 am

SEE

Sealed Air Corporation (SEE) has revised its FY23 adjusted EPS outlook downwards from $3.50 - $3.80 to $2.75 - $2.95, which is below the estimated $3.43.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:18 am

CRNX

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q2 losses of $(0.94) per share, missing the analyst consensus estimate of $(0.86) by 9.3%. This is a 16.05% decrease from the same period last year. However, the company reported quarterly sales of $988.00K, beating the analyst consensus estimate of $560.00K by 76.43%, a 125.06% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:18 am

SEE

Sealed Air Corporation has reduced its FY23 revenue forecast from $5.85B-$6.10B to $5.40B-$5.60B, which is below the estimated $5.86B.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:17 am

TDG

TransDigm Gr (NYSE:TDG) reported Q3 adjusted earnings of $7.25 per share, beating the analyst consensus estimate of $6.33 by 14.53%. This is a 49.48% increase from the same period last year. The company also reported quarterly sales of $1.74 billion, beating the analyst consensus estimate of $1.68 billion by 4.00%, a 24.75% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:16 am

RPRX

Royalty Pharma Plc (NASDAQ:RPRX) has updated its FY23 adjusted cash receipts guidance to $2.90B-$2.975B, up from the previous guidance of $2.850B-$2.950B. This represents an underlying growth of 6% to 10% prior to the Zavzpret milestone payment in Q1 2023 and the payments related to the Biohaven Preferred Shares received in 2022.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:15 am

ITOS

ITeos Therapeutics reported Q2 losses of $(0.96) per share, a 740% decrease from the same period last year. The company's cash balance and investment balance of $677.5M is expected to provide runway into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:15 am

SEE

Sealed Air (NYSE:SEE) reported Q2 adjusted earnings of $0.80 per share, beating the analyst consensus estimate of $0.68 by 17.65%. However, this is a 20.79% decrease from the same period last year. The company's quarterly sales of $1.38 billion missed the analyst consensus estimate of $1.42 billion by 2.54%, marking a 2.68% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:14 am